20,455 Shares in Journey Medical Co. (NASDAQ:DERM) Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP purchased a new position in shares of Journey Medical Co. (NASDAQ:DERM) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 20,455 shares of the company’s stock, valued at approximately $80,000. Dimensional Fund Advisors LP owned approximately 0.10% of Journey Medical as of its most recent SEC filing.

Insiders Place Their Bets

In related news, CEO Claude Maraoui sold 4,834 shares of the stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $6.84, for a total transaction of $33,064.56. Following the completion of the sale, the chief executive officer now directly owns 2,348,313 shares of the company’s stock, valued at approximately $16,062,460.92. This represents a 0.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders sold 113,522 shares of company stock valued at $589,229. 15.03% of the stock is currently owned by insiders.

Journey Medical Stock Performance

Shares of NASDAQ:DERM opened at $6.93 on Monday. The stock has a market capitalization of $160.11 million, a P/E ratio of -7.37 and a beta of 0.86. Journey Medical Co. has a 1-year low of $3.20 and a 1-year high of $8.24. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 1.81. The business has a 50-day moving average price of $6.44 and a two-hundred day moving average price of $5.42.

Journey Medical (NASDAQ:DERM) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.06. The firm had revenue of $13.14 million during the quarter, compared to analysts’ expectations of $12.05 million. Journey Medical had a negative return on equity of 132.10% and a negative net margin of 31.74%. Equities analysts predict that Journey Medical Co. will post -1.02 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Industrial Alliance Securities set a $10.50 price target on shares of Journey Medical in a research report on Thursday, March 27th. Alliance Global Partners reiterated a “buy” rating on shares of Journey Medical in a research report on Thursday, March 27th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $9.88.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.